Andrea Cercek
Memorial Sloan Kettering Cancer Center · 610 works · 33,251 citations · h-index 61
Top works
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- Colorectal cancer statistics, 2020
- Colorectal cancer statistics, 2023
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
- Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy
- Neoadjuvant Chemotherapy Without Routine Use of Radiation Therapy for Patients With Locally Advanced Rectal Cancer: A Pilot Trial
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline
- Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
- Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels
- Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas
- Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
- Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients
- Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer
- Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
- Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial